Adjunctive ruxolitinib attenuates inflammation and enhances immunity in volunteers experimentally infected with Plasmodium falciparum

Overview of attention for article published in Science Translational Medicine, November 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

news: 3 news outlets
blogs: 1 blog
twitter: 21 X users

facebook: 1 Facebook page
bluesky: 10 Bluesky users

Readers on

mendeley: 17 Mendeley

So far, Altmetric has seen 11 Bluesky posts from 10 Bluesky users, with an upper bound of 144,285 followers.

RP @sciencex.bsky.social: A medication used for certain blood disorders, ruxolitinib, may help improve recovery and immune response when combined with standard treatment for severe malaria. Further studies are needed. doi.org/hbkjmt

A medication used for certain blood disorders, ruxolitinib, may help improve recovery and immune response when combined with standard treatment for severe malaria. Further studies are needed. doi.org/hbkjmt

Wow I did *not* have "*blocking* JAK/STAT" on my "how to improve malaria vaccines" BINGO card www.science.org/doi/10.1126/...

RP @science.org: The approved medication ruxolitinib dampens inflammatory responses to malaria and can enhance immune memory to the parasite in infected volunteers, supporting its potential as an adjunctive therapy to improve outcomes. #ScienceTranslati…

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity, including 7 additional Bluesky posts.